Nephrotoxicity Assays

The nephrotoxicity toxicity assays provide a means to measure renal dysfunction due to the toxic effect of a test compound. We provide nephrotoxicity assays for all small molecule formulations such as pharmaceuticals, industrial chemicals and consumer products.

Our nephrotoxicity assays use a genetically modified version of a renal proximal tubular epithelial cell (RPTEC) created with our proprietary CompoZr® zinc finger (ZFN) nuclease technology.

Kidney toxicity is a continuing concern during drug development. In particular, RPTECs are frequently affected due to their roles in filtrate resorption and concentration as well as drug clearance. Although primary human kidney cells are available and a handful of immortalized kidney cell lines currently exist, there is a need for improved assay systems.

We genetically modified human primary renal proximal tubule epithelial cells in order to enable extended cell proliferation. The resulting cell line has been characterized for the presence of proximal tubule cell markers as well as several functional properties, including transporter activity and response to known human nephrotoxicants. We offer nephrotoxicity screening in this human RPTEC cell line using the MTT assay for cell viability as the primary endpoint. Additional endpoints may be added or substituted upon request.
 

 Nephrotoxicity Assay Protocol

 
Test System RPTEC (human)
Test Compound Concentration 1 -300 µM in half log increments, or custom
Replicates 3
Assay Length 48 hours
Controls Vehicle (0.1% DMSO)
Cisplatin
Analysis Method MTT, absorbance
Data Delivery IC50

Click here to contact an expert today for your nephrotoxicity testing needs.